

Special Issue

Cyclodextrin-Based Delivery Systems for Anticancer Drugs

Message from the Guest Editors

Malignant diseases are one of the most powerful diseases of the current century, representing a major cause of death globally. Besides the screening of synthetic molecules with anticancer potential, natural compounds represent a valuable alternative to the limitations of conventional chemotherapy. Natural compounds also face drawbacks that limit their utilization, such as poor water solubility, low dissolution rate, bioavailability, and increased sensitivity to degradation and inactivation. Cyclodextrins are, nowadays, considered valuable pharmaceutical excipients due to their ability to partly or completely include a drug molecule, thus improving the unfavorable physicochemical and the biological properties of the hosted molecule. Currently, the development of improved formulations based on natural and synthetic compounds with increased bioavailability and stability, along with dose reduction and the reduction in adverse effects, represent topical issues. This Special Issue will bring together recent data regarding the role of cyclodextrins in developing improved delivery systems containing anticancer compounds.

Guest Editors

Dr. Cristina Trandafirescu

Dr. Iulia Pinzaru

Dr. Denisa Laura Ivan

Deadline for manuscript submissions

closed (10 November 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/108939

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).